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Abstract 
Rationale: How nasal symptoms in patients with COPD change over time and resolve during 
natural occurring exacerbation has never been described. 
Methods: Patients in the London COPD cohort were asked about the presence of nasal 
symptoms (nasal discharge, sneezing, post-nasal drip (PND), blocked nose and anosmia) 
over an 8-year period (2005-2013) every three months at routine clinic visits at stable state 
and daily during exacerbations with the use of diary cards. Data was prospectively collected 
and in a subgroup of patients COPD Assessment Test (CAT) and human rhinovirus (HRV) 
identification by PCR was available. Patients were also defined as infrequent/frequent 
exacerbators (<2 or ≥2 exacerbations/year). 
Measurements and Main Results: On 4368 visits, 209 patients with COPD were asked about 
their nasal symptoms. On 2033 visits, when the patients were stable, the odds ratio (OR) for 
nasal discharge increased by 1.32% per year (95% CI 1.19-1.45; p<0.001); sneezing 1.16% 
(1.05-1.29; p=0.005); post-nasal drip 1.18% (1.03-1.36; p=0.016) and anosmia 1.19% (1.03-
1.37; p=0.015). At exacerbation, nasal discharge was present for 7-daysand blocked nose, 
sneezing and post-nasal drip increased for just 3 days; anosmia did not change. Nasal 
discharge was more likely in frequent exacerbators; OR 1.96 (1.17-3.28; p=0.011) and when 
present, COPD Assessment Test scores were higher by 1.06 units (0.32-1.80; p=0.005) when 
stable and 1.30 units (0.05 to 2.57; p=0.042) at exacerbation. 
Conclusion: Upper airway symptoms increase over time in COPD patients and are related to 
the frequent exacerbator phenotype. These longitudinal changes may be due to increasing 
airway inflammation or the disease progression. 
 
Abstract Word Count: 242  
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Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality 
1
.The natural history of COPD is characterized by the repeated occurrence of episodes called 
exacerbations that are manifested by an inflammatory response, mediated predominantly 
by neutrophils that increase respiratory symptoms 
2,3
. 
 It is widely known that there is an association between rhinitis and asthma since 90% 
of patients with asthma have rhinitis and almost 30% of patients with allergic rhinitis 
develop asthma 
4
. In COPD, nasal symptoms are not considered important, and sometimes 
they are neglected, as the disease is thought to be primarily due to airflow limitation in the 
lung 
5
. However, whenever a person inhales smoke from tobacco or biomass fuels, the 
smoke penetrates into the whole airway from nose to distant alveoli. We have previously 
described the presence of chronic nasal and respiratory symptoms in COPD patients 
6
, the 
relationship of the upper airway to lower airway bacteria 
7
, the impact of nasal symptoms 
on quality of life 
8
 and the correlation of systemic inflammation both in upper and lower 
airways during exacerbation 
9
. The concept that COPD is a “pan-airway” disease in COPD is 
gaining support with different groups publishing data that strengthen the epidemiological 
evidence 
10,11
. 
However, there is no evidence that the prevalence or severity of nasal symptoms 
changes over time and forms part of the natural progression of the disease and neither the 
influence on health status, as assessed with the COPD Assessment Test (CAT) score. The 
concept of time-related worsening of nasal symptoms in mature population have been 
reported and shown that despite fairly low self-reported prevalence of these disorders in 
large population studies, when validated, there is a high prevalence of hyposmia and 
anosmia in certain groups, especially the elderly
12
.  
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Some explanations regarding toxic exposure, head trauma, autoimmunity, or aging 
itself can contribute to smell impairment, with different implications concerning prognosis 
and possible treatment. Often, the ENT specialists are the one that identify in first place 
these symptoms in patients with chronic rhinosinusitis.  
Thus, the aim of this study was to evaluate the evolution and impact of upper airway 
symptoms in a well-defined COPD cohort when stable and at exacerbation.  
 
Methods 
 
Study Subjects and Protocol 
A total of 209 patients enrolled in the London COPD Cohort were included between March 
2005 and June 2013 (with at least one year of participation in the cohort). A complete 
flowchart on the visits and collected data is shown in Figure 1. The post-bronchodilator 
forced expiratory volume in 1 second (FEV1) of all patients was ≤80% predicted from age, 
height, and sex and a FEV1/Forced Vital Capacity (FVC) ratio <0.7 
5
. A history of smoking, 
including smoking status and medical history were recorded. Data on nasal steroid sprays 
were collected from May 2010 onwards.  
 
Definition of Exacerbation and Monitoring 
Patients were also asked to record on a daily diary card any increase or occurrence in their 
lower airway symptoms. Dyspnoea, sputum purulence and sputum volume were defined as 
major symptoms and nasal discharge/congestion, wheeze, sore throat and cough were 
defined as minor symptoms. Exacerbations were defined as previously used by the London 
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COPD Cohort 
13
, as any change in one major symptom with at least one other (major or 
minor) for two consecutive days.  
The annual exacerbation frequency was calculated for each patient using the 
number of days the patients had completed their diary between January 2005 and June 
2013. Patients were then defined as infrequent exacerbators (<2 exacerbations/year) or 
frequent group (≥2/year) 
14
. 
 
Nasal Symptoms 
All subjects were asked about the presence of nasal symptoms (runny nose/nasal discharge, 
sneezing, post-nasal drip (PND), blocked nose or anosmia /impaired smell) in the three-
months prior to their quarterly stable clinic review. From March 2011 - June 2013 (Figure 1) 
patients were asked to grade the severity of their nasal symptoms (0 = no symptom, 1 = very 
mild, 2=mild, 3=moderate, 4=severe and 5=bad as can be). At exacerbation and during 
recovery they were asked if there was a presence of these five nasal symptoms on each day. 
For the purpose of this study, runny nose and nasal discharge are considered equivalent 
terms.  
 
Quality of Life Assessment Using the CAT Score 
In a subgroup of patients (Figure 1), during the stable baseline state and during 
exacerbations, patients were asked to complete the CAT at least once under supervision in 
clinic and once at home. The stable state was defined when more than 35 days after and 21 
days before exacerbation onset. If the baseline CAT scores before exacerbation onset were 
unavailable, the score during post-exacerbation stability was used.  
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Sputum Collection and Processing 
At a number of the clinic visits (Figure 1), spontaneously expectorated sputum was 
collected. Quantitative Polymerase Chain Reaction (qPCR) was used to detect human 
rhinovirus using the ABI Prism 7500 Real-time qPCR System (Applied Biosystems) and 
validated primers 
15
. 
 
Statistical Analysis 
For the statistical analyses, Stata 13 (Stata Corp, Texas, USA) was used and data were 
expressed as percentages, mean ± SEM or median + inter-quartile range. Comparisons 
between independent groups were made by chi-squared test, Student's t-test or Wilcoxon 
sign-rank test respectively. The correlations between the means of independent groups 
were evaluated with Pearson correlation test. A p-value < 0.05 was considered statistically 
significant.  
Trends over time were first assessed in a univariate analysis with random-effect 
logistic regression models that allowed for repeated measures in the same individual. These 
trends were then assessed into a multi-variate model that included smoking status and 
exacerbation frequency phenotype and their interaction with time. To assess whether nasal 
symptoms at exacerbation rose faster overtime compared to baseline nasal symptom, we 
also included in the multivariate model a term describing whether the data was recorded at 
baseline or exacerbation and its interaction with time. Results are reported as odds ratio for 
a 1-year interval with 95% confidence interval.  
An analysis of variance was used to compare the severity of symptom over various 
time periods during the onset and recovery of exacerbation with data recorded at baseline. 
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Random effects models that adjusted for repeated measures were used also for the analysis 
of the CAT score and its impact on nasal symptoms.  
The Ethical Committee of the Royal Free Hospital granted approval for this study and 
all patients gave informed written consent.  
 
Results 
 
Demography 
Table 1 shows the main characteristics of the 209 COPD patients included. The mean FEV1 
was 1.22 L (0.46); FEV1 as % predicted 50.1% (SD 16.4), age was 70.7 years (SD 8.7). Of the 
population, 130 were male (62 %) and 66 (32%) were current smokers. A total of 13/140 
(9.3%) of patients on whom data was available, have been receiving nasal corticosteroids at 
some time. Due to the relation between bronchiectasis and sinusitis, none of the patients 
included for the purpose of this study had clinical findings of bronchiectasis (large volume of 
sputum or coarse crepitations) during clinical history or examination. 
 
Nasal Symptoms at Baseline and Changes over Time 
Data on nasal symptoms from 209 stable patients were recorded on 2033 clinic visits. Figure 
2 shows that the overall prevalence of these symptoms increased over time. In a univariate 
analysis all the nasal symptoms increased over time in the overall population (all symptoms, 
all patients, p<0.05), but in the multivariate analysis, the odds ratio (OR) for a runny 
nose/nasal discharge increased over time independently of exacerbation frequency or 
smoking status by 1.32% per year (95% CI 1.19-1.45; p<0.001); sneezing 1.16% (1.05-1.29; 
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p=0.005); post-nasal drip 1.18% (1.03-1.36; p=0.016) and anosmia 1.19% (1.03-1.37; 
p=0.015) but not blocked nose OR=1.01% (0.90-1.14; p=0.811). 
However, nasal discharge was more likely in frequent exacerbators; OR 1.96 (1.17-
3.28; p=0.011). Current smokers were also more likely to experience impaired 
smell/anosmia: OR 2.47 (1.06-5.80; p= 0.037). 
 
Time Course of Nasal Symptoms during Exacerbations 
Nasal symptoms were recorded during exacerbation between onset on day 0 and day 42 on 
2197 visits; 838 visits were between 0 to +7 days of exacerbation onset. Of these 838 
occasions, only the incidence of a nasal discharge and post-nasal drip increased over time, 
with OR 1.18 (1.09-1.29; p<0.001) and 1.20 (1.08-1.33; p<0.001) respectively, but these 
longitudinal changes were not significant after adjustment for smoking, frequent/infrequent 
exacerbator phenotype or interactions with time. The combination of the exacerbation data 
with the baseline data did not show any differences in the increased prevalence of nasal 
symptoms over time between the stable and exacerbation state.  
 
Time Course of Nasal Severity Score 
Figure 3 shows the severity of nasal symptoms at baseline, prodrome (days -7 to -1), onset 
(0-3 days) and during recovery from exacerbation in the overall population. In comparison 
with the baseline, nasal scores for runny nose/nasal discharge were higher on days 0-3 and 
days 4-7 (p<0.001 and p<0.001 respectively). Symptoms of a blocked nose, post-nasal drip 
and sneezing appeared to resolve faster than nasal discharge as scores where significantly 
higher on days 0-3 (p=0.006, p=0.001 and p=0.005 respectively) but by days 4-7 were not 
significantly different from baseline (p=0.693, p=0.069 and p=0.128 respectively). The 
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severity of anosmia did not change at exacerbation. The nasal severity scores were not 
higher than baseline on days during the prodrome (days -7 to -1) or during the later stages 
of exacerbation recovery, days 8-14, days 15-29 or days 29 to 42. 
 
CAT Score and Nasal Symptoms 
In a subgroup of patients (May 2011-June 2013) as stated in Figure 1, the CAT questionnaire 
was completed on 728 of the 2033 baseline visits and 347 of the 838 exacerbation visits in 0 
to +7 days. Figure 4 shows that the CAT score were significantly different between baseline 
and at exacerbation in those with nasal discharge symptoms as it increased by 1.06 units 
(0.32-1.80; p=0.005) and by 1.30 (0.05 to 2.57; p=0.042) respectively. CAT scores were 
higher by 3.6 units in frequent exacerbators but there was no difference in the effect of a 
runny nose on the CAT score between frequent and infrequent exacerbators (p=0.062). The 
presence of any of the other nasal symptoms was not associated with differences in the CAT 
score.  
 
Associations of Nasal Symptoms with Human Rhinovirus (HRV) 
In a subgroup of patients, there were 311visits when qPCR on sputum samples collected was 
performed (Figure 1). HRV was detected only in 42/122 (34.4%) sputum samples when 
symptoms of a blocked nose were present compared to 44/188 when symptoms were 
absent (23.4%; p=0.034). Moreover42/122(34.4%) positive samples coincided with sneezing 
but only 42/188 (22.3%; p=0.019) when this symptom was absent. With a nasal discharge, 
the percentages were 58.2% compared to 48.2% (p=0.083); post nasal-drip 22.1% vs 21.7%; 
(p=0.927) and for anosmia 11.5% vs 9.0%; (p=0.485).  
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Discussion 
 
This study for the first time shows that nasal symptoms in stable COPD patients increase 
progressively and shows their time-course during naturally occurring exacerbations. This 
study also relates the presence of nasal discharge to the frequent exacerbator phenotype. 
Moreover these data has been prospectively collected over a wide period of time (8 years) 
in a very well characterised cohort of COPD patients.. 
In a previous study by our group 
6
, we found a prevalence of nasal symptoms of 75%, 
with 52% of patients reporting nasal discharge and 45.9% reported sneezing. That study 
showed a trend towards increased nasal symptoms in frequent exacerbators compared to 
infrequent exacerbators, and that nasal symptoms were independent of smoking status. In 
the current study of 209 patients, we found that runny nose/nasal discharge was more 
common in frequent exacerbators, but none of the other symptoms were as strongly linked 
as this one to this phenotype. Nasal blockage and anosmia/impaired smell was more 
prevalent in current smokers. 
Two clinical findings need to be emphasized in this study. First, the presence of nasal 
symptoms was different according to the frequent exacerbator phenotype, especially the 
presence of runny nose/nasal discharge. This may be in part due to impairment of 
mucociliary function in these patients and the increased mucosal inflammation in the upper 
airways as previously described 
16
.Second, although some of the patients were former 
smokers, the nasal symptoms continued worsening over time in both frequent and 
infrequent exacerbators, strengthening the hypotheses that once prolonged smoke 
exposure arrives at a threshold, the inflammatory stimuli cannot easily be switched-off 
17
. 
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With experimental human models of exacerbations, it is known that the majority of 
patients experience worsening in both upper respiratory (sneezing, post-nasal drip, runny 
nose/nasal discharge) and lower symptoms 
18
. Our study is the first to describe the time 
course during exacerbations typical of those seen in the community and triggered by 
viruses, bacteria or pollution. As expected at exacerbations in the overall population, nasal 
discharge was the most common symptom (frequent and infrequent patients) at the onset, 
together with post-nasal drip, with both symptoms worsening during the first seven days. 
Post-nasal drip, blocked nose and sneezing as symptoms appeared in the early 
stages of exacerbation during the first three days, but these symptoms recovered faster. 
This clinical evolution of nasal symptoms at exacerbation was not related to the clinical 
phenotype or the current or past smoking exposure.  
It is important to mention that not all-nasal symptoms recorded were related to the 
presence of the most common respiratory virus (HRV as the cause of common cold) during 
exacerbations. Only nasal discharge and sneezing were consistently associated with HRV in 
all frequent/infrequent patients and these symptoms may be useful in identifying some 
exacerbations that may be early treated with anti-viral medications. This finding also agrees 
with studies concerning the transmission of respiratory viruses, since these agents were 
present in almost 50% of exacerbations
19
. 
Anosmia/impaired smell did not change over the time of the exacerbation even at 
the onset when both lower and the other upper respiratory symptoms were at their worse. 
No differences in anosmia were found in regards to being a frequent or infrequent 
exacerbator patient. However, in general population, 70.5% of women and just 29.5% of 
men report a worsening of anosmia either during or post-upper respiratory tract infection
20
. 
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It is possible that since our cohort is of 62% male COPD subjects, they were less likely to 
report a worsening of this symptom. 
During the study a subgroup of patients completed the CAT questionnaire. This is a 
validated eight-item questionnaire designed to assess and quantify the impact of COPD 
symptoms on patient health status
21
 but it has been also shown to be a good tool in 
measuring severity 
22
 and recovery from exacerbations
23
. It also has two principal 
advantages in that it can be used in different clinical settings (primary care and second care) 
and shows no variability between languages
24
. 
Among all the nasal symptoms explored, only nasal discharge showed a rise in the 
CAT score, both in the stable state and during exacerbations as it was also the most 
prevalent symptom in our population during stable state and during exacerbations . 
Although it has not been properly established, a change of 1.6 units in the CAT score has 
been suggested as a threshold in the variation of the CAT score to arrive to the minimal 
clinically important difference 
24
.In our study we showed a rise that might not be significant, 
but our study opens a new study area, regarding the impact of nasal symptoms on the CAT 
score in COPD. 
A potential limitation of the study must be addressed, as we do not have sinus CT-
scans or ENT examination of all the patients (to assess the presence or absence of nasal 
polyps) but there is some evidence that the symptoms in both populations (with and 
without polyps) usually overlap
25
. We also do not have information on the possible presence 
of patients with the criteria for the asthma and COPD overlap syndrome as recently 
described by GINA-GOLD
26
. 
Airway bacterial colonisation (BC) is common in latest phases of COPD and is well 
known that sputum samples correlate with bacteria isolated from lower airways by 
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bronchoscopic samples
27,28
.The presence of bacteria increases local inflammation of the 
bronchi and elevation of systemic inflammatory biomarkers 
29
. However, few studies have 
investigated bacterial colonisation of the upper airway in COPD patients
7
. Further studies in 
this field are needed to clarify the pathogenics of the sinonasal symptoms. 
Some strains of the common microorganisms often associated with acute 
exacerbations (Non-typeable H. Influenzae, M. catarrhalis) can form biofilms. This could lead 
to biofilm-associated chronic rhinosinusitis. Although, several studies aimed at preventing 
biofilm formation with topical antimicrobials, surfactants, loop diuretics and macrolides 
have been tested
30
, none of these interventions have been studied in COPD patients.  
A pilot study on 33 patients has recently been published on the use of nasal 
corticosteroids (fluticasone furoate) and showed that in patients assigned to the treatment 
group, there was a decrease of nasal IL-8 after 12 weeks of treatment and an amelioration 
of nasal symptoms 
31
. However, little information is known on the frequent/infrequent 
phenotype in this paper or the response of eosinophilic inflammation (eotaxin response) in 
response to the use of nasal corticosteroids. A larger trial with more clinical characterisation 
in COPD patients is warranted. 
In conclusion, we have shown that nasal symptoms are part of the natural evolution 
of COPD and that they worsen over time and are closely related to the frequent exacerbator 
phenotype. These symptoms should be taken into account when performing 
multidimensional evaluations of the patients, since they might also impact on assessment 
scores and health-related quality of life.  
 
Acknowledgments: The authors want to acknowledge Siobhan George for her outstanding 
work doing the qPCR for rhinovirus in the cohort samples.  
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 Table 1. Demographics on population studied at the London COPD cohort 
 N = 209 
Age (years) 70.7 (SD 8.7) 
Gender (male) % 130 (62%) 
Smoking (%) 
Current smoker 
Former smoker 
 
66 (31%) 
143 (68%) 
COPD 
Stage II 
Stage III 
Stage IV 
 
106 (50.7%) 
75 (35.9%) 
28 (13.4%) 
FEV1 (L) 1.22 (0.46) 
FEV1 % predicted (SD) 50.1% (16.5) 
FVC (L) 2.65 (0.87) 
FEV1/FVC ratio 0.47 (0.12) 
Number of exacerbations in the prior year 
(median + interquartile range) 
1.92 (1-3.1) 
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Figure Legends 
Figure 1. Flowchart of COPD patients included, data collected and samples processed during 
8-years (2005-2013) in the London COPD cohort. 
 
Figure 2. Percentage of patient-reported symptoms over time in the London COPD Cohort. 
Number refers to the number of visits where patients reported having nasal symptoms.   
 
Figure 3. Time course of nasal symptoms during exacerbations in the London COPD Cohort 
graded and divided by clusters of days. 
 
Figure 4. Effect of nasal discharge during stable state and at exacerbation and its impact on 
the CAT score. 
 
Figure 5. Time course of nasal symptoms during exacerbations in patients with infrequent 
and frequent exacerbations.* p<0.05, chi-squared test. 
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Figure 1. Flowchart of COPD patients included, data collected and samples processed during 8-years (2005-
2013) in the London COPD cohort.  
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Figure 2. Percentage of patient-reported symptoms over time in the London COPD Cohort. Number refers to 
the number of visits where patients reported having nasal symptoms  
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Figure. 3 Time course of nasal symptoms during exacerbations in the London COPD Cohort graded and 
divided by clusters of days.  
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Figure 4. Effect of nasal discharge during stable state and at exacerbation and its impact on the CAT score.  
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Figure. 5 Time course of nasal symptoms during exacerbations in patients with infrequent and frequent 
exacerbations.* p<0.05, chi-squared test.  
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